相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir
Chunfu Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
James C. Sullivan et al.
CLINICAL INFECTIOUS DISEASES (2013)
ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2013)
VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668
Q. Huang et al.
JOURNAL OF HEPATOLOGY (2013)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Yoshiyuki Suzuki et al.
JOURNAL OF HEPATOLOGY (2013)
SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
I. Jacobson et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Doug J. Bartels et al.
JOURNAL OF VIROLOGY (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients
Mariana E. Kirst et al.
PLOS ONE (2013)
In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335
Lisette Lagace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
Angela M. Lam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients
Hadas Dvory-Sobol et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir
S. Le Pogam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
Fred Poordad et al.
GASTROENTEROLOGY (2012)
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
Stefan Zeuzem et al.
HEPATOLOGY (2012)
Characterization of Telaprevir Treatment Outcomes and Resistance in Patients With Prior Treatment Failure: Results From the REALIZE Trial
Sandra De Meyer et al.
HEPATOLOGY (2012)
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: A randomized phase II study
Michael P. Manns et al.
HEPATOLOGY (2012)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS
G. Kukolj et al.
JOURNAL OF HEPATOLOGY (2012)
TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL
O. Lenz et al.
JOURNAL OF HEPATOLOGY (2012)
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin
Dominique Larrey et al.
JOURNAL OF HEPATOLOGY (2012)
INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2012)
2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL
S. Zeuzem et al.
JOURNAL OF HEPATOLOGY (2012)
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
Eric J. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
CHARACTERIZATION OF HCV VARIANTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS ADMINISTERED THE COMBINATION OF TVR AND VX-222 IN DUAL ARMS OF ZENITH STUDY
E. Z. Zhang et al.
JOURNAL OF HEPATOLOGY (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naive and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
Tara L. Kieffer et al.
PLOS ONE (2012)
Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
Xiomara V. Thomas et al.
PLOS ONE (2012)
Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients
Stefania Paolucci et al.
VIROLOGY JOURNAL (2012)
Protease Inhibitor-Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
Tetsuro Shimakami et al.
GASTROENTEROLOGY (2011)
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
Stefan Zeuzem et al.
GASTROENTEROLOGY (2011)
Multiple Ascending Dose Study of BMS-790052, a Nonstructural Protein 5A Replication Complex Inhibitor, in Patients Infected with Hepatitis C Virus Genotype 1
Richard E. Nettles et al.
HEPATOLOGY (2011)
Antiviral Activity of the Hepatitis C Virus Polymerase Inhibitor Filibuvir in Genotype 1 Infected Patients
Frank Wagner et al.
HEPATOLOGY (2011)
Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell et al.
HEPATOLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN
S. Zeuzem et al.
JOURNAL OF HEPATOLOGY (2011)
GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF NS3 VARIANTS SELECTED IN HCV-INFECTED PATIENTS TREATED WITH ABT-450
T. Pilot-Matias et al.
JOURNAL OF HEPATOLOGY (2011)
MOLECULAR CHARACTERIZATION OF HCV RESISTANCE TO TELAPREVIR BY MEANS OF ULTRA-DEEP PYROSEQUENCING: PREEXISTING RESISTANT VARIANTS AND DYNAMICS OF RESISTANT POPULATIONS
S. Chevaliez et al.
JOURNAL OF HEPATOLOGY (2011)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2011)
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
Michael P. Manns et al.
JOURNAL OF HEPATOLOGY (2011)
The global health burden of hepatitis C virus infection
Francesco Negro et al.
LIVER INTERNATIONAL (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
RESISTANCE PROFILE OF ABT-333 AND RELATIONSHIP TO VIRAL LOAD DECREASE IN PATIENTS TREATED IN COMBINATION WITH PEG-INTERFERON AND RIBAVIRIN FOR 28 DAYS
T. Middleton et al.
JOURNAL OF HEPATOLOGY (2010)
RG7128 Alone or in Combination with Pegylated Interferon-α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV-Infected Patients
Sophie Le Pogam et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
Keith P. Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected Patients
Simone Susser et al.
HEPATOLOGY (2009)
Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
Jose M. Cuevas et al.
JOURNAL OF VIROLOGY (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy
Phillip S. Pang et al.
PLOS ONE (2009)
Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice
Stephane Chevaliez et al.
PLOS ONE (2009)
The Global Spread of Hepatitis C Virus 1a and 1b: A Phylodynamic and Phylogeographic Analysis
Gkikas Magiorkinis et al.
PLOS MEDICINE (2009)
Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479
Samir Ali et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Characterization of resistance mutations against HCV ketoamide protease inhibitors
Xiao Tong et al.
ANTIVIRAL RESEARCH (2008)
Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel
Martin S. Hirsch et al.
CLINICAL INFECTIOUS DISEASES (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system
Yupeng He et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants -: Sensitivity to telaprevir (VX-950) and interferon α
Yi Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
Xiao Tong et al.
ANTIVIRAL RESEARCH (2006)
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
P Simmonds et al.
HEPATOLOGY (2005)
Genetic diversity and evolution of hepatitis C virus - 15 years on
P Simmonds
JOURNAL OF GENERAL VIROLOGY (2004)
分享论文
